Rhythm Pharmaceuticals, Inc. (RYTM)

NASDAQ: RYTM · Real-Time Price · USD

92.73

-5.34 (-5.45%)

At close: Feb 27, 2026, 4:00 PM EST

92.66

-0.07 (-0.08%)

After-hours: Feb 27, 2026, 7:32 PM EST

-5.45% (1D)

Market Cap	6.33B
Revenue (ttm)	189.76M
Net Income (ttm)	-201.92M
Shares Out	68.29M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,322,301
Open	96.66
Previous Close	98.07
Day's Range	90.84 - 97.81
52-Week Range	45.91 - 122.20
Beta	2.04
Analysts	Strong Buy
Price Target	130.57 (+40.81%)
Earnings Date	Feb 26, 2026

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 5, 2017

Employees 283

Stock Exchange NASDAQ

Ticker Symbol RYTM

Website https://rhythmtx.com

Full Company Profile

Financial Performance

In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $130.57, which is an increase of 40.81% from the latest price.

Price Target

$130.57

(40.81% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -...

5 hours ago - GlobeNewsWire

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript

3 days ago - Seeking Alpha

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic ob...

3 days ago - GlobeNewsWire

Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), citing it as a commercial-stage biotech pioneering the rare genetic obesity market.

10 days ago - Benzinga

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...

12 days ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...

24 days ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preli...

7 weeks ago - GlobeNewsWire

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show ...

2 months ago - Seeking Alpha

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript

2 months ago - Seeking Alpha

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) stock is higher on Thursday, after the company shared preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi s...

2 months ago - Benzinga

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising re...

2 months ago - GlobeNewsWire

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...

2 months ago - GlobeNewsWire

Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress

Rhythm Pharmaceuticals, Inc. maintaining a Strong Buy rating, driven by IMCIVREE's growth and multiple late-stage expansion opportunities in rare genetic obesity indications. RYTM's IMCIVREE awaits FD...

3 months ago - Seeking Alpha

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data ...

3 months ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a gl...

4 months ago - GlobeNewsWire

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...